{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:51:03Z","timestamp":1794351063489,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"QuantumLeap"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1245\/s10434-025-16973-y","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:28:52Z","timestamp":1739438932000},"page":"3278-3291","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from &gt; 1500 Patients on the I-SPY2 Clinical Trial"],"prefix":"10.1245","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3228","authenticated-orcid":false,"given":"Judy C.","family":"Boughey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayla","family":"Switalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladores","family":"Velle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel B.","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantal R.","family":"Reyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Jaskowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Tchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshni","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpana M.","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehra","family":"Golshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cletus A.","family":"Arciero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice A. M.","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy B.","family":"Matsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Yau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Esserman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita A.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the I-SPY2 Locoregional Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"11","key":"16973_CR1","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1002\/1097-0142(19920601)69:11<2849::AID-CNCR2820691134>3.0.CO;2-P","volume":"69","author":"SE Singletary","year":"1992","unstructured":"Singletary SE, McNeese MD, Hortobagyi GN. Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. Cancer. 1992;69(11):2849\u201352.","journal-title":"Cancer."},{"issue":"7","key":"16973_CR2","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1200\/JCO.1997.15.7.2483","volume":"15","author":"B Fisher","year":"1997","unstructured":"Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997;15(7):2483\u201393.","journal-title":"J Clin Oncol."},{"issue":"22","key":"16973_CR3","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","volume":"376","author":"N Masuda","year":"2017","unstructured":"Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. New Engl J Med. 2017;376(22):2147\u201359.","journal-title":"New Engl J Med."},{"issue":"7","key":"16973_CR4","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. New Engl J Med. 2019;380(7):617\u201328.","journal-title":"New Engl J Med."},{"issue":"32","key":"16973_CR5","doi-asserted-by":"crossref","first-page":"5213","DOI":"10.1200\/JCO.2008.16.3725","volume":"26","author":"SA McLaughlin","year":"2008","unstructured":"McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol. 2008;26(32):5213\u20139.","journal-title":"J Clin Oncol."},{"issue":"14","key":"16973_CR6","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJM199810013391401","volume":"339","author":"D Krag","year":"1998","unstructured":"Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer\u2013a multicenter validation study. New Engl J Med. 1998;339(14):941\u20136.","journal-title":"New Engl J Med."},{"issue":"10","key":"16973_CR7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"DN Krag","year":"2007","unstructured":"Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol. 2007;8(10):881\u20138.","journal-title":"Lancet Oncol."},{"issue":"12","key":"16973_CR8","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.2005.05.188","volume":"23","author":"EP Mamounas","year":"2005","unstructured":"Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from national surgical adjuvant breast and bowel project protocol B-27. J Clin Oncol. 2005;23(12):2694\u2013702.","journal-title":"J Clin Oncol."},{"key":"16973_CR9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/SLA.0b013e3181b8fd5e","volume":"250","author":"KK Hunt","year":"2009","unstructured":"Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250:558\u201366.","journal-title":"Ann Surg."},{"issue":"14","key":"16973_CR10","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","volume":"310","author":"JC Boughey","year":"2013","unstructured":"Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455\u201361.","journal-title":"JAMA."},{"issue":"7","key":"16973_CR11","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","volume":"14","author":"T Kuehn","year":"2013","unstructured":"Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609\u201318.","journal-title":"Lancet Oncol."},{"issue":"3","key":"16973_CR12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","volume":"33","author":"JF Boileau","year":"2015","unstructured":"Boileau JF, Poirier B, Basik M, Holloway CMB, Gaboury L, Sideris L, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol. 2015;33(3):258-U150.","journal-title":"J Clin Oncol."},{"issue":"3","key":"16973_CR13","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1245\/s10434-021-10830-4","volume":"29","author":"TM Khan","year":"2022","unstructured":"Khan TM, Rossi AJ, Suman V, Haffty B, Hernandez JM, Boughey JC. Is axillary radiation not inferior to axillary dissection for sentinel lymph node-positive breast cancer after neoadjuvant chemotherapy? Ann Surg Oncol. 2022;29(3):1526\u20137.","journal-title":"Ann Surg Oncol."},{"issue":"11","key":"16973_CR14","doi-asserted-by":"crossref","first-page":"6401","DOI":"10.1245\/s10434-023-13759-y","volume":"30","author":"JC Boughey","year":"2023","unstructured":"Boughey JC, Yu H, Dugan CL, Piltin MA, Postlewait L, Son JD, et al. Changes in surgical management of the axilla over 11 years: report on more than 1500 breast cancer patients treated with neoadjuvant chemotherapy on the prospective I-SPY2 trial. Ann Surg Oncol. 2023;30(11):6401\u201310.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"16973_CR15","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1245\/s10434-012-2531-z","volume":"19","author":"AS Caudle","year":"2012","unstructured":"Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, et al. American college of surgeons oncology group (ACOSOG) Z0011: impact on surgeon practice patterns. Ann Surg Oncol. 2012;19(10):3144\u201351.","journal-title":"Ann Surg Oncol."},{"issue":"4","key":"16973_CR16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.clbc.2017.10.007","volume":"18","author":"A Weiss","year":"2018","unstructured":"Weiss A, Mittendorf EA, DeSnyder SM, Hwang RF, Bea V, Bedrosian I, et al. Expanding implementation of ACOSOG Z0011 in surgeon practice. Clin Breast Cancer. 2018;18(4):276\u201381.","journal-title":"Clin Breast Cancer."},{"issue":"6","key":"16973_CR17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjsurg.2014.08.009","volume":"208","author":"KA Robinson","year":"2014","unstructured":"Robinson KA, Pockaj BA, Wasif N, Kaufman K, Gray RJ. Have the American college of surgeons oncology group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection? Am J Surg. 2014;208(6):1060\u20134.","journal-title":"Am J Surg."},{"issue":"1","key":"16973_CR18","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jamcollsurg.2015.02.035","volume":"221","author":"K Yao","year":"2015","unstructured":"Yao K, Liederbach E, Pesce C, Wang CH, Winchester DJ. Impact of the American college of surgeons oncology group Z0011 randomized trial on the number of axillary nodes removed for patients with early-stage breast cancer. J Am Coll Surg. 2015;221(1):71\u201381.","journal-title":"J Am Coll Surg."},{"issue":"4","key":"16973_CR19","doi-asserted-by":"crossref","first-page":"e477","DOI":"10.1016\/j.clbc.2017.09.001","volume":"18","author":"JM Mann","year":"2018","unstructured":"Mann JM, Wu X, Christos P, Nagar H. The state of surgical axillary management and adjuvant radiotherapy for early-stage invasive breast cancer in the modern era. Clin Breast Cancer. 2018;18(4):e477\u201393.","journal-title":"Clin Breast Cancer."},{"issue":"10","key":"16973_CR20","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1245\/s10434-016-5310-4","volume":"23","author":"MW Tsao","year":"2016","unstructured":"Tsao MW, Cornacchi SD, Hodgson N, Simunovic M, Thabane L, Cheng J, et al. A population-based study of the effects of a regional guideline for completion axillary lymph node dissection on axillary surgery in patients with breast cancer. Ann Surg Oncol. 2016;23(10):3354\u201364.","journal-title":"Ann Surg Oncol."},{"issue":"10","key":"16973_CR21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2017.11470","volume":"318","author":"AE Giuliano","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918\u201326.","journal-title":"JAMA."},{"issue":"3","key":"16973_CR22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/SLA.0000000000001863","volume":"264","author":"AE Giuliano","year":"2016","unstructured":"Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American college of surgeons oncology group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg. 2016;264(3):413\u201320.","journal-title":"Ann Surg."},{"issue":"8","key":"16973_CR23","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/1097-0142(19811015)48:8<1863::AID-CNCR2820480825>3.0.CO;2-U","volume":"48","author":"B Fisher","year":"1981","unstructured":"Fisher B, Wolmark N, Redmond C, Deutsch M, Fisher ER. Findings from NSABP protocol No. B-04: comparison of radical mastectomy with alternative treatments. II. The clinical and biologic significance of medial-central breast cancers. Cancer. 1981;48(8):1863\u201372.","journal-title":"Cancer."},{"issue":"3","key":"16973_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/SLA.0b013e3181f08f32","volume":"252","author":"AE Giuliano","year":"2010","unstructured":"Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases. Ann Surg. 2010;252(3):426\u201333.","journal-title":"Ann Surg."},{"issue":"6","key":"16973_CR25","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","volume":"305","author":"AE Giuliano","year":"2011","unstructured":"Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569\u201375.","journal-title":"JAMA."},{"issue":"12","key":"16973_CR26","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S1470-2045(14)70460-7","volume":"15","author":"M Donker","year":"2014","unstructured":"Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981\u201322023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303\u201310.","journal-title":"Lancet Oncol."},{"issue":"24","key":"16973_CR27","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1200\/JCO.2006.07.4062","volume":"25","author":"A Lucci","year":"2007","unstructured":"Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American college of surgeons oncology group trial Z0011. J Clin Oncol. 2007;25(24):3657\u201363.","journal-title":"J Clin Oncol."},{"issue":"9","key":"16973_CR28","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","volume":"98","author":"RE Mansel","year":"2006","unstructured":"Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst. 2006;98(9):599\u2013609.","journal-title":"J Natl Cancer Inst."},{"issue":"2","key":"16973_CR29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jso.21535","volume":"102","author":"T Ashikaga","year":"2010","unstructured":"Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010;102(2):111\u20138.","journal-title":"J Surg Oncol."},{"key":"16973_CR30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jss.2023.08.004","volume":"292","author":"GB Peery","year":"2023","unstructured":"Peery GB, Pak J, Burkbauer L, Agala CB, Selfridge JM, Gallagher KK, et al. Omission of axillary dissection in node positive breast cancer after neoadjuvant systemic therapy. J Surg Res. 2023;292:247\u201357.","journal-title":"J Surg Res."},{"issue":"13","key":"16973_CR31","doi-asserted-by":"crossref","first-page":"8813","DOI":"10.1245\/s10434-024-16143-6","volume":"31","author":"JN Limberg","year":"2024","unstructured":"Limberg JN, Jones T, Thomas SM, Ntowe KW, Dalton JC, van den Bruele AB, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. Ann Surg Oncol. 2024;31(13):8813\u201320.","journal-title":"Ann Surg Oncol."},{"issue":"6","key":"16973_CR32","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1245\/s10434-018-6429-2","volume":"25","author":"TA Moo","year":"2018","unstructured":"Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, et al. Is low-volume disease in the sentinel node after neoadjuvant chemotherapy an indication for axillary dissection? Ann Surg Oncol. 2018;25(6):1488\u201394.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"16973_CR33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10549-011-1891-6","volume":"133","author":"AJ Lowery","year":"2012","unstructured":"Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat. 2012;133(3):831\u201341.","journal-title":"Breast Cancer Res Treat."},{"issue":"19","key":"16973_CR34","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","volume":"98","author":"T Sorlie","year":"2001","unstructured":"Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98(19):10869\u201374.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"16973_CR35","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.surg.2018.06.021","volume":"164","author":"KE Larson","year":"2018","unstructured":"Larson KE, Valente SA, Tu C, Dalton J, Grobmyer SR. Surgeon-associated variation in breast cancer staging with sentinel node biopsy. Surgery. 2018;164(4):680\u20136.","journal-title":"Surgery."},{"issue":"2","key":"16973_CR36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10549-020-05843-8","volume":"184","author":"JM Dixon","year":"2020","unstructured":"Dixon JM, Grewar J, Twelves D, Graham A, Martinez-Perez C, Turnbull A. Factors affecting the number of sentinel lymph nodes removed in patients having surgery for breast cancer. Breast Cancer Res Treat. 2020;184(2):335\u201343.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"16973_CR37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1186\/s13063-018-3021-9","volume":"19","author":"G Henke","year":"2018","unstructured":"Henke G, Knauer M, Ribi K, Hayoz S, Gerard MA, Ruhstaller T, et al. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 2018;19(1):667.","journal-title":"Trials."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-16973-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-16973-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T03:08:48Z","timestamp":1744081728000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-16973-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["16973"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-16973-y","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"11 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Judy C. Boughey reports an institutional research grant from Eli Lilly and SimBioSys; royalties from UpToDate; honoraria from EndoMag, PER, PeerView and OncLive; and travel support from EndoMag and Alliance for Clinical Trials in Oncology. She is a member of the Data Safety and Monitoring Committee for Cairns Surgical; serves on the Board of Directors for ASBS; and is an unpaid working group Chair at the Society of Surgical Oncology (SSO) Breast Disease Site. Chantal R. Reyna reports consulting fees from Elucent, honoraria for visiting professor grand rounds, and honoraria from the Japanese Team Science Oncology Program for a facilitator and leadership role for the Association of Women Surgeons Secretary. Marie C. Lee reports an institutional research grant and honoraria from Elucent Medical; participation on the Provepharm Advisory Board; and owns stock in J&J. Mehra Golshan reports funding from the Breast Cancer Research Foundation. Candice A.M. Sauder serves on the Executive Committee of the American Joint Committee on Cancer (AJCC). Cindy B. Matsen reports receiving personal research grants from the Utah Cancer Action Network (Principal Investigator [PI]), Department of Defense (co-Investigator [co-I]), and the National Institutes of Health (NIH; co-I); institutional research funding from the Department of Defense; honoraria from Memorial Sloan Kettering Cancer Center Breast Surgical Oncology Fellows; US patent no. US8207142B2; participation on the Data Safety Monitoring Board for the trial of a patient education tool for an NIH-funded trial; participation on the Ethics Committee of the American Society of Breast Surgeons; and was the SSO representative for the American Society for Radiation Oncology Guidelines Working Group. Christina Yau reports an institutional research grant from the National Cancer Institute (NCI)\/NIH; salary and travel support from Quantum Leap Healthcare Collaborative; University of California Inventor Share; and the patent \u2018Breast Cancer Response Prediction Subtypes\u2019 (No. 18\/174,491). Laura Esserman reports institutional research funding from Moderna for a DCIS trial; publishing royalties from UpToDate; and travel support from and participation on the Medical Advisory Board at Blue Cross Blue Shield. Rita A. Mukhtar reports research support and honoraria from GE Healthcare and the NCI; institutional research funding from the University of California San Francisco; and is an unpaid member of the Scientific Advisory Board for the Lobular Breast Cancer Alliance. Hongmei Yu, Kayla Switalla, Ladores Velle, Alex Lopes, Anne M. Wallace, Rachel B. Lancaster, Todd M. Tuttle, Nora Jaskowiak, Julia Tchou, Roshni Rao, Arpana M. Naik, and Cletus A. Arciero did not report any disclosures that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}